Stepping on Roche's toes, Merck cuts into SCLC niche with third-line Keytruda OK
In the increasingly crowded checkpoint race, small cell lung cancer has been a rare area where Roche, a second runner-up, has a lead over the entrenched leaders Merck and Bristol-Myers Squibb. But Merck is finally making some headway in that direction with the latest approval for its PD-1 star.
The latest green light endorses Keytruda in the third-line treatment of metastatic SCLC, where it would be given to patients whose disease either don’t respond to or relapse after chemotherapy, which would have followed at least one prior line of therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.